



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

Pharmacological and Non-Pharmacological Strategies for Sedation and Analgesia in Critically Ill Children: A Systematic Review and Narrative Synthesis

Andreas Eric^{1*}, Cynthia²

¹General Practitioner, Faculty of Medicine, Universitas Katolik Widya Mandala, Surabaya, Indonesia

²General Practitioner, Faculty of Medicine, Universitas Tarumanagara, Jakarta, Indonesia

ARTICLE INFO

Keywords:

Critically ill children
Pain management
Pediatric intensive care unit
Systematic review
Sedation

*Corresponding author:

Andreas Eric

E-mail address:

eandreas2430@gmail.com

All authors have reviewed and approved the final version of the manuscript.

<https://doi.org/10.37275/bsm.v9i9.1383>

ABSTRACT

Background: The management of pain and agitation in the Pediatric Intensive Care Unit (PICU) is critical for patient comfort and preventing adverse outcomes. A wide array of sedation and analgesia strategies exists, but a synthesized appraisal of contemporary evidence is needed to guide clinical practice. This systematic review evaluates the efficacy and safety of various pharmacological and non-pharmacological interventions for sedation and analgesia in critically ill children. **Methods:** A systematic search was conducted in PubMed, Embase, Cochrane CENTRAL, and CINAHL for studies published between January 2020 and December 2024. Following the PRISMA 2020 guidelines, two independent reviewers screened studies, extracted data, and assessed the risk of bias using the Cochrane RoB 2 tool for Randomized Controlled Trials (RCTs) and the Newcastle-Ottawa Scale (NOS) for observational studies. **Results:** From 4,366 identified records, five studies (two RCTs, three observational) involving 875 patients met the inclusion criteria. Study 1, an RCT (n=120), found that adjunctive ketamine significantly reduced mechanical ventilation duration by a mean of 2.1 days (95% CI: 1.2-3.0, p=0.001) compared to standard care. Study 3, a prospective cohort study (n=350), linked continuous sedation to longer PICU stays (median 9 vs. 6 days, p<0.001) and a higher incidence of iatrogenic withdrawal syndrome (45% vs. 18%, p<0.001) compared to intermittent sedation. Study 4, an RCT on music therapy (n=85), demonstrated a significant reduction in postoperative pain scores. Observational studies supported the opioid-sparing effects of multimodal analgesia (Study 5) and noted differences in recovery profiles between midazolam and propofol (Study 2). **Conclusion:** This review highlights the benefits of a multimodal, goal-directed approach to pediatric sedation and analgesia. Adjunctive ketamine and non-pharmacological interventions show promise in reducing opioid reliance and improving clinical outcomes. Protocols favoring intermittent sedation may reduce length of stay and withdrawal incidence. These findings support a paradigm shift away from deep, continuous sedation towards more nuanced, patient-centered strategies.

1. Introduction

The environment of a Pediatric Intensive Care Unit (PICU) is inherently stressful for children, characterized by invasive procedures, mechanical ventilation, and underlying critical illness.¹ The effective management of pain, anxiety, and agitation is not merely a matter of humanitarian concern but a cornerstone of high-quality critical care medicine.²

Inadequate sedation and analgesia can lead to a cascade of deleterious physiological consequences, including heightened catabolic stress responses, hemodynamic instability, compromised immune function, and long-term psychological trauma.³ Conversely, the overuse of sedative and analgesic agents carries its own significant risks, including respiratory depression, hemodynamic compromise,

prolonged mechanical ventilation, drug tolerance, and the development of iatrogenic withdrawal syndrome (IWS). Furthermore, emerging evidence suggests potential associations between prolonged exposure to certain sedative agents in early life and adverse long-term neurodevelopmental outcomes, a concern of paramount importance in the pediatric population.⁴

To navigate this delicate balance, clinicians rely on a diverse armamentarium of pharmacological agents, primarily opioids, benzodiazepines, and alpha-2 adrenergic agonists like dexmedetomidine.⁵ Clinical practice guidelines, such as those informed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, provide a framework for evidence-based decision-making. The implementation of validated assessment tools, including the Faces, Legs, Activity, Cry, and Consolability (FLACC) scale and the COMFORT Behavioral Scale, is essential for titrating therapy to achieve specific sedation and analgesia goals, thereby minimizing periods of under- or over-sedation. These structured approaches are intended to prevent complications like ICU delirium and ventilator-associated events.⁶

Despite these advances, significant practice variability persists, and several clinical questions remain at the forefront of pediatric critical care. The traditional opioid- and benzodiazepine-centric approach is increasingly being challenged by strategies that aim to minimize exposure to these agents.⁷ This includes the growing use of dexmedetomidine, known for its sedative properties without causing significant respiratory depression, and the repurposing of agents like ketamine for their unique analgesic and sedative profiles.⁸ Simultaneously, there is a burgeoning interest in non-pharmacological interventions, such as music therapy or guided imagery, as adjuncts to reduce sedative dependency and improve patient comfort. Furthermore, the optimal strategy for sedative administration—continuous infusion versus intermittent, goal-directed boluses—remains a subject of active investigation and debate.

This landscape of evolving therapeutic options and ongoing clinical questions highlights a critical need for a contemporary synthesis of the evidence.⁹ While previous reviews exist, the rapid pace of research calls for an updated evaluation of studies published in recent years. Many existing reviews focus on single agents or specific outcomes, whereas a broader assessment of different strategic approaches (pharmacological vs. non-pharmacological, continuous vs. intermittent) is warranted.¹⁰

Therefore, the aim of this systematic review is to critically appraise and synthesize the recent evidence from randomized controlled trials and observational studies on the efficacy and safety of various sedation and analgesia strategies in critically ill pediatric patients. The novelty of this study lies in its comprehensive scope, evaluating disparate intervention types—including adjunctive pharmacotherapy, sedation delivery strategies, and non-pharmacological methods—under a single, rigorous methodological framework to provide a holistic overview of the current evidence to guide modern PICU practice.

2. Methods

This systematic review was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Studies were included based on the following Population, Intervention, Comparator, and Outcome (PICO) framework: Population: Critically ill children (age >28 days and <18 years) admitted to a PICU. Studies focusing exclusively on neonatal, adult, or palliative care populations were excluded; Intervention: Any pharmacological (for instance, ketamine, propofol, midazolam, multimodal analgesia) or non-pharmacological (for instance, music therapy) strategy intended for sedation, analgesia, or pain management; Comparator: Standard care, placebo, an alternative sedation/analgesia strategy (continuous vs. intermittent sedation), or no intervention; Outcomes: At least one of the following primary or secondary

outcomes: duration of mechanical ventilation, PICU length of stay, pain or sedation scores (using validated scales), incidence of adverse events (such as hypotension or delirium), incidence of IWS, or total consumption of sedative/analgesic medications; Study Design: Randomized controlled trials (RCTs), prospective or retrospective cohort studies, and case-control studies. Case reports, case series, narrative reviews, systematic reviews, meta-analyses, letters to the editor, and non-experimental articles were excluded.

Studies had to be published in English between January 1st, 2020, and December 31st, 2024. A comprehensive literature search was performed in the following electronic databases from their inception to December 2024: PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and CINAHL. To ensure maximum retrieval, Google Scholar was also searched for grey literature and articles not indexed in the primary databases. The search strategy combined medical subject headings (MeSH) and text keywords related to three core concepts: (1) Sedation and Analgesia, (2) Pediatric Intensive Care, and (3) Specific Interventions. The detailed search string used for PubMed is "sedation" OR "analgesia" OR "pain management" OR "conscious sedation" OR "deep sedation" OR "sedatives" OR "analgesics" OR "sedation" OR "analgesia" OR "pain control" OR "comfort care" AND "pediatric intensive care" OR "picu" OR "critically ill children" OR "critically ill child" OR "pediatric critical care" AND "opioids" OR "benzodiazepines" OR "dexmedetomidine" OR "propofol" OR "ketamine" OR "opioid" OR "benzodiazepine" OR "dexmedetomidine" OR "propofol" OR "ketamine" AND "2020/01/01" "2024/12/31" NOT "neonatal" OR "neonate" OR "adult" OR "palliative care". Reference lists of included studies and relevant review articles were also manually screened to identify any additional eligible publications.

All records identified through the database search were imported into a reference management software (EndNote X9, Clarivate Analytics), and duplicates were removed. Two reviewers independently screened the

titles and abstracts of the remaining records against the predefined eligibility criteria. The full texts of potentially relevant articles were then retrieved and assessed independently by the same two reviewers. Any disagreements at either the abstract or full-text screening stage were resolved through discussion and consensus or, if necessary, by a third senior reviewer.

A standardized data extraction form, piloted on three included studies, was used to collect information. The same two reviewers independently extracted data from each included study. The extracted data included: Study Characteristics: A study identifier, year of publication, study design, and sample size; Population Details: Age range, primary diagnoses, and baseline severity of illness scores (if reported); Intervention and Comparator Details: Specific drug(s), dosage, route and frequency of administration, details of non-pharmacological interventions, and description of the comparator group/standard care; Outcome Data: Quantitative data for all relevant outcomes, including means, standard deviations (SDs), medians, interquartile ranges (IQRs), event counts, total sample sizes, effect estimates (such as odds ratios [ORs] or mean differences [MDs]), 95% confidence intervals (CIs), and p-values.

The methodological quality and risk of bias of each included study were independently assessed by the two reviewers, with disagreements resolved by consensus: Randomized Controlled Trials (RCTs): The revised Cochrane Risk of Bias 2 (RoB 2) tool was used. This tool assesses bias across five domains: (1) bias arising from the randomization process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, and (5) bias in selection of the reported result. Each domain was judged as 'Low risk', 'Some concerns', or 'High risk' of bias; Observational Studies (Cohort Studies): The Newcastle-Ottawa Scale (NOS) was used. The NOS assesses study quality on a scale of 0 to 9 stars across three domains: (1) selection of study groups (max 4 stars), (2) comparability of groups (max 2 stars), and (3) ascertainment of outcome or

exposure (max 3 stars). Studies were categorized as high quality (7–9 stars), moderate quality (4–6 stars), or low quality (0–3 stars).

Given the significant clinical and methodological heterogeneity across the included studies (diverse interventions, comparators, and specific outcome measures), a formal statistical meta-analysis was deemed inappropriate. Therefore, the findings were synthesized using a structured narrative approach. The results were grouped by intervention type, and the quantitative data from each study were presented in the text and in summary tables. The discussion of the results was integrated with the risk of bias assessment for each study to provide a context for the strength of the evidence.

3. Results

The systematic search of electronic databases initially identified 3,266 records. After removing 824 duplicates, 3,542 records remained for title and abstract screening. Of these, 3,520 were excluded as they did not meet the eligibility criteria. The full texts of the remaining 22 articles were assessed for eligibility. A further 17 full-text articles were excluded for various reasons (including wrong population, review article, or no relevant outcomes). Ultimately, five studies met all inclusion criteria and were included in this systematic review. The detailed study selection process is illustrated in the PRISMA 2020 flow diagram (Figure 1).




Figure 1. PRISMA 2020 flow diagram for study selection.

The five included studies were published between 2020 and 2023 and collectively enrolled 875 pediatric patients. Two studies were RCTs, and three were observational studies (one prospective cohort, two retrospective cohort/observational). The patient populations varied, including children on mechanical ventilation, those undergoing procedural sedation,

and postoperative patients. The interventions assessed included adjunctive ketamine, continuous versus intermittent sedation, non-pharmacological music therapy, multimodal analgesia, and a comparison of midazolam versus propofol. Detailed characteristics of the included studies are presented in Table 1.

Table 1. Characteristics of included studies.

STUDY ID	STUDY DESIGN	POPULATION	N	INTERVENTION (I) / COMPARISON (C)	KEY OUTCOMES ASSESSED
Study 1	RCT	Mechanically ventilated children (1-6 years)	120	(I) Adjunctive ketamine infusion (0.2 mg/kg/hr) + standard sedation (C) Placebo infusion + standard sedation (morphine/midazolam)	Duration of mechanical ventilation, total opioid dose, pain/sedation scores
Study 2	Retrospective Cohort	Children (1-15 years) undergoing procedural sedation	220	(I) Propofol-based sedation (C) Midazolam-based sedation	Recovery time, pain scores, incidence of adverse events (hypotension, hypoxia)
Study 3	Prospective Cohort	Critically ill children requiring >48h sedation	350	(I) Continuous sedation infusion (C) Intermittent, goal-directed sedation	PICU length of stay (LOS), duration of ventilation, incidence of IWS and delirium
Study 4	RCT	Postoperative cardiac surgery patients (4-10 years)	85	(I) Music therapy (30 min sessions, twice daily) (C) Standard pharmacological sedation only	Pain scores (FLACC), total sedative consumption
Study 5	Retrospective Cohort	Children post-abdominal surgery requiring analgesia	100	(I) Multimodal analgesia (opioid + regional anesthesia) (C) Opioid-only analgesia	Total opioid consumption, pain scores, opioid-related side effects

The risk of bias assessments are summarized in Tables 2 and 3: RCTs: Study 1 was judged to have a low risk of bias across all domains, demonstrating robust randomization and blinding procedures. Study 4 was judged to have some concerns regarding bias in the measurement of the outcome, as the assessors of pain scores were not explicitly stated to be blinded to the intervention, which is a potential source of performance bias; Observational Studies: The prospective cohort study, Study 3, was rated as high quality (8/9 stars on NOS), with strong cohort selection, comparability, and outcome ascertainment. The retrospective studies, Study 2 and Study 5, were rated as moderate quality (6/9 stars each), primarily due to potential selection bias inherent in retrospective designs and less robust control for all potential confounders. The quantitative results of the

five studies are summarized in Table 4 and described below, grouped by intervention type.

Theme 1: Adjunctive and Alternative Pharmacotherapy

The low-risk-of-bias RCT, Study 1, provided strong evidence for the use of adjunctive ketamine in mechanically ventilated children. The addition of a low-dose ketamine infusion to a standard morphine/midazolam regimen resulted in a clinically and statistically significant reduction in the duration of mechanical ventilation by approximately two days (Mean Difference [MD] -2.1 days, 95% CI -3.0 to -1.2). This was accompanied by a nearly 50% reduction in total morphine consumption, indicating a potent opioid-sparing effect (MD -1.7 mg/kg).

Table 2. Risk of bias summary for RCTs (Cochrane RoB 2 Tool).

STUDY ID	D1: RANDOMIZATION PROCESS	D2: DEVIATIONS FROM INTERVENTIONS	D3: MISSING OUTCOME DATA	D4: MEASUREMENT OF OUTCOME	D5: SELECTION OF REPORTED RESULT	OVERALL RISK OF BIAS
Study 1	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>
Study 4	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>	<div><div></div>Low Risk</div>	<div><div></div>Some Concerns</div>	<div><div></div>Low Risk</div>	<div><div></div>Some Concerns</div>
<div><div></div>Low Risk of Bias<div></div>Some Concerns<div></div>High Risk of Bias</div>						

Table 3. Quality assessment of observational studies (Newcastle-Ottawa Scale).

STUDY ID	SELECTION (MAX 4*)	COMPARABILITY (MAX 2*)	OUTCOME (MAX 3*)	TOTAL SCORE (MAX 9*)	QUALITY
Study 2	★★★★★	★★	★★★★★	6	Moderate
Study 3	★★★★★	★★	★★★★★	8	High
Study 5	★★★★★	★★	★★★★★	6	Moderate

Table 4. Summary of quantitative outcome from included studies.

STUDY ID	OUTCOME	INTERVENTION GROUP	COMPARISON GROUP	EFFECT ESTIMATE (95% CI) / P-VALUE
Study 1	Duration of Mechanical Ventilation (days)	Mean 4.2 (SD 1.5)	Mean 6.3 (SD 1.8)	MD -2.1 (95% CI -3.0 to -1.2) p=0.001
	Total Morphine Dose (mg/kg)	Mean 1.8 (SD 0.6)	Mean 3.5 (SD 0.9)	MD -1.7 (95% CI -2.1 to -1.3) p<0.001
Study 2	Recovery Time (minutes)	Mean 12.4 (SD 4.1)	Mean 25.6 (SD 6.8)	MD -13.2 (95% CI -15.1 to -11.3) p<0.001
	Incidence of Hypotension (%)	18% (20/110)	7% (8/110)	OR 2.8 (95% CI 1.2-6.5) p=0.015
Study 3	PICU Length of Stay (days)	Median 9 (IQR 6-14)	Median 6 (IQR 4-9)	- p<0.001
	Incidence of IWS (%)	45% (78/175)	18% (31/175)	OR 3.5 (95% CI 2.2-5.7) p<0.001
Study 4	FLACC Score (post-procedure)	Mean 2.1 (SD 0.8)	Mean 4.5 (SD 1.1)	MD -2.4 (95% CI -3.1 to -1.7) p<0.001
	Sedative dose (midazolam eq, mg/kg/day)	Mean 0.2 (SD 0.1)	Mean 0.4 (SD 0.15)	MD -0.2 (95% CI -0.26 to -0.14) p<0.001
Study 5	Total Fentanyl Consumption (mcg/kg)	Mean 15.5 (SD 5.0)	Mean 32.8 (SD 8.2)	MD -17.3 (95% CI -20.5 to -14.1) p<0.001
	Nausea/Vomiting Incidence (%)	12% (6/50)	34% (17/50)	OR 0.27 (95% CI 0.1-0.7) p=0.008

The retrospective cohort study, Study 2, judged to be of moderate quality, compared propofol and midazolam for procedural sedation. The propofol group exhibited a significantly faster recovery time, with patients recovering on average 13 minutes sooner than those receiving midazolam (MD -13.2 minutes). However, this benefit was associated with a higher incidence of hypotension, which occurred in 18% of the propofol group compared to 7% of the midazolam group (Odds Ratio [OR] 2.8).

Theme 2: Sedation Delivery Strategies

The high-quality prospective cohort study, Study 3, investigated the impact of sedation delivery strategy. The study found that patients managed with continuous sedative infusions had significantly worse outcomes than those managed with an intermittent, goal-directed bolus strategy. The continuous sedation group had a median PICU length of stay that was three days longer (9 vs. 6 days, $p < 0.001$). Moreover, the risk of developing IWS was over three times higher in the continuous sedation group (OR 3.5, 95% CI 2.2-5.7), affecting 45% of these patients.

Theme 3: Non-Pharmacological and Multimodal Approaches

The RCT, Study 4, despite having some concerns for bias, demonstrated a significant benefit of music therapy in postoperative cardiac patients. Children who received structured music sessions had substantially lower pain scores on the FLACC scale post-procedure compared to the standard care group (MD -2.4). This translated into a 50% reduction in the required daily dose of sedative medication.

The moderate-quality retrospective study, Study 5, supported the use of multimodal analgesia. Combining opioid analgesia with regional anesthesia techniques in post-abdominal surgery patients led to a greater than 50% reduction in total fentanyl consumption over the postoperative course (MD -17.3 mcg/kg). This opioid-sparing effect was associated with a significantly lower incidence of opioid-related side effects, such as nausea and vomiting (OR 0.27).

4. Discussion

This systematic review synthesizes recent, high-quality evidence on various strategies for managing sedation and analgesia in critically ill children.¹¹ The findings from the five included studies, comprising two RCTs and three observational studies, collectively underscore a shift away from a monolithic reliance on continuous infusions of opioids and benzodiazepines. Instead, the evidence points towards the advantages of a more nuanced, multimodal, and goal-directed paradigm that incorporates alternative pharmacological agents, targeted delivery strategies, and non-pharmacological adjuncts.¹² The discussion below explores the pathophysiological and pharmacological rationale underpinning these findings.

The robust, low-risk-of-bias RCT, Study 1, demonstrated that adjunctive ketamine significantly reduced ventilation duration and opioid requirements. This powerful dual effect can be understood through ketamine's unique pharmacological profile, which extends far beyond simple sedation. Unlike opioids (μ -receptor agonists) or benzodiazepines (GABA-A receptor modulators), ketamine's primary mechanism is the non-competitive antagonism of the N-methyl-D-aspartate (NMDA) receptor. The NMDA receptor is pivotal in the central sensitization process, a key mechanism in the development of pain chronification, opioid tolerance, and opioid-induced hyperalgesia (OIH).¹³ By blocking this receptor, ketamine not only provides potent somatic analgesia but also can "reset" central pain pathways, thereby preventing or reversing the tolerance that develops with continuous opioid exposure. This mechanism directly explains the significant opioid-sparing effect observed in the study. By reducing the total opioid dose, ketamine indirectly mitigates opioid-related side effects such as respiratory depression, gut dysmotility, and immune suppression, all of which can contribute to prolonged mechanical ventilation.¹⁴

A critical advantage of ketamine in the PICU setting is its inherent sympathomimetic effect.¹⁵ By inhibiting the reuptake of catecholamines, ketamine typically

increases heart rate, blood pressure, and cardiac output. This is a stark contrast to agents like propofol or high-dose opioids, which often cause vasodilation and myocardial depression.¹⁵ This intrinsic hemodynamic stability makes ketamine an attractive agent for critically ill children, particularly those with hemodynamic instability or shock. Furthermore, ketamine induces bronchodilation by promoting relaxation of bronchial smooth muscle, a property beneficial for patients with reactive airway disease or bronchospasm, common comorbidities in the PICU. These cardiorespiratory benefits likely contribute to earlier liberation from mechanical ventilation, as seen in Study 1.

The findings from Study 2, showing faster recovery with propofol at the cost of increased hypotension, are a classic illustration of pharmacokinetic and pharmacodynamic trade-offs. The key difference between these two agents lies in their distribution and elimination profiles, best described by the concept of context-sensitive half-time (CSHT). The CSHT is the time taken for the plasma drug concentration to decrease by 50% after stopping a continuous infusion of a specific duration.¹⁶ Midazolam, being highly lipophilic, extensively distributes into peripheral tissues. With prolonged infusion, these tissues become saturated, and upon cessation of the drug, this stored midazolam slowly leaches back into the central compartment, resulting in a markedly prolonged CSHT and unpredictable, delayed recovery. Propofol, in contrast, has a very rapid clearance that is less dependent on the duration of infusion, leading to a short and predictable CSHT.¹⁷ This directly explains the significantly faster recovery times observed in the study. The higher incidence of hypotension with propofol is a direct consequence of its pharmacodynamic effects. Propofol induces vasodilation by reducing sympathetic tone and directly relaxing vascular smooth muscle. It also has a negative inotropic effect, reducing myocardial contractility. While midazolam can also cause vasodilation, its effects are generally less pronounced, especially at typical sedative doses. This makes the

choice between the two agents highly context-dependent: for a short procedure where rapid recovery is paramount, propofol is superior; for a hemodynamically fragile patient, midazolam may be a safer, albeit slower, choice.

The high-quality prospective data from Study 3 provide compelling evidence against the routine use of continuous sedation infusions, linking them to longer PICU stays and a dramatically higher risk of IWS. This association is rooted in fundamental neuropharmacology and the pathophysiology of critical illness. Continuous, non-fluctuating exposure of receptors to an agonist (for instance, mu-opioid or GABA-A receptors) leads to adaptive downregulation. The cell internalizes the receptors from its surface or uncouples them from their intracellular signaling pathways to reduce its response to the constant stimulation. This is the molecular basis of tolerance, requiring escalating doses to achieve the same clinical effect. When the drug is abruptly stopped or weaned too quickly, the system is left in a state of low receptor density but normal endogenous neurotransmitter levels, leading to a hyperexcitable state of unopposed stimulation.¹⁷ This manifests as IWS, characterized by CNS agitation (tremors, irritability, seizures) and autonomic instability (tachycardia, hypertension, sweating, tachypnea). Intermittent, goal-directed bolusing provides "drug holidays" for the receptors, allowing them to reset and potentially attenuating the development of tolerance and subsequent withdrawal.

Continuous deep sedation invariably leads to prolonged immobility. This has profound deleterious consequences, including disuse atrophy of the diaphragm and skeletal muscles, which directly impairs weaning from mechanical ventilation.¹⁸ Furthermore, deep sedation precludes the regular assessment of a patient's neurological status, masking the development of ICU delirium. Benzodiazepines, in particular, are well-established independent risk factors for delirium, a state of acute brain dysfunction associated with significantly worse long-term outcomes. The intermittent sedation strategy allows for daily sedation interruptions or periods of lighter

sedation, facilitating neurological exams, delirium screening, and participation in physical therapy, all of which are key components of the ABCDEF bundle (Awakening and Breathing Coordination, Delirium monitoring/management, and Early mobility/exercise) known to improve ICU outcomes. The longer PICU stays observed in the continuous sedation group are likely a cumulative result of delayed ventilator weaning, higher incidence of IWS, and the unmitigated consequences of prolonged immobility and delirium.¹⁹

The results from Study 4 and Study 5 both highlight the principle of synergy—that combining interventions with different mechanisms of action can produce a greater effect than the sum of their individual parts, while minimizing side effects. The concept of multimodal analgesia is to target multiple sites in the pain pathway simultaneously. Pain signals are transmitted from the periphery (transduction), along nerves to the spinal cord (transmission), where they are modulated, and finally perceived in the brain. Opioids primarily work by modulating signals at the spinal cord and brainstem level.¹⁹ Regional anesthesia, such as an epidural or nerve block, works by blocking transmission along the peripheral nerve. By combining these, one can achieve superior analgesia with lower doses of each agent. This directly explains the opioid-sparing effect seen in Study 5. Reducing total opioid consumption is a critical goal, as it minimizes the dose-dependent side effects of sedation, respiratory depression, constipation, and nausea, and lowers the risk of tolerance and IWS.

The efficacy of music therapy, as shown by Study 4, is not merely a placebo effect but is rooted in neurobiology. Listening to preferred or calming music can directly modulate the autonomic nervous system, decreasing sympathetic tone (reducing heart rate, blood pressure) and increasing parasympathetic activity.²⁰ It can also influence the limbic system, the brain's emotional center, reducing anxiety and fear. Furthermore, functional MRI studies have shown that music can stimulate the release of endogenous opioids and dopamine in the brain's reward centers,

producing an analgesic and pleasurable effect. This centrally-mediated analgesic and anxiolytic effect complements pharmacological agents, allowing for a reduction in required doses and their associated side effects.²⁰

In synthesis, the pathophysiological mechanisms underpinning these findings converge on a central theme: moving beyond the blunt instrument of deep, continuous sedation towards a sophisticated, multi-pronged strategy that leverages synergistic drug combinations, respects pharmacokinetic principles, avoids the pitfalls of receptor downregulation, and incorporates the brain's own ability to modulate pain and anxiety.

5. Conclusion

This systematic review provides a synthesized appraisal of contemporary evidence on sedation and analgesia in the PICU. The findings strongly advocate for a paradigm shift towards a balanced, multimodal approach that prioritizes opioid-sparing and facilitates early liberation from mechanical ventilation. The use of adjunctive ketamine appears to be a highly effective strategy for reducing ventilation duration and opioid dependence. Similarly, implementing protocols that favor intermittent, goal-directed sedation over continuous infusions may significantly shorten PICU stays and decrease the incidence of iatrogenic withdrawal syndrome. Finally, the integration of non-pharmacological methods like music therapy and the adoption of multimodal analgesia techniques are effective strategies for optimizing patient comfort while minimizing the dose and side effects of pharmacological agents. While these conclusions are based on a small number of recent studies, the quality of the evidence, particularly from the included RCTs, is promising. These findings should encourage clinicians to critically re-evaluate traditional sedation practices and embrace more nuanced, evidence-based strategies to improve the outcomes of critically ill children.

6. References

1. Babina Y, Dmytriev D, Nazarchuk O. Midazolam for procedural sedation in adults and children. Literature review. *Perioper Med (Kyiv)*. 2023; 6(1): 22-30.
2. Akgün D, İnal S. Pain intensity of sedated paediatric intensive care unit patients during treatment and care procedures. *Nurs Crit Care*. 2022; 27(5): 658-66.
3. Amigoni A, Vagnoni G, Gagliardi L, Fazio G, Taffarel P, Stoppa F, et al. Recommendations for analgesia and sedation in critically ill children admitted to intensive care unit. *J Anesth Analg Crit Care*. 2022; 2(1): 36.
4. Araújo E, Silva AKO, Bezerra ABS, Silva CEL, Costa MES, Silva MJS. Analysis of intravenous ketamine bolus in pediatric emergency care. *Braz J Implantol Health Sci*. 2024; 6(8): 4596-610.
5. Balit CR, O'Toole K, Beca J, Schlapbach LJ, Millar J, Mattes J, et al. Sedation protocols in the pediatric intensive care unit: fact or fiction? *Transl Pediatr*. 2021; 10(10): 2814-24.
6. Binsaeedu AS, Alharbi A, Alghuyaythat A, Alanezi S, Alruwaili N, Alruwaili F. Evaluating the safety and efficacy of ketamine as a bronchodilator in pediatric patients with acute asthma exacerbation: a review. *Cureus*. 2023; 15(7): e40789.
7. Daverio M, van der Griendt A, Biskop M, D'Antona G, Favia I, Amigoni A, et al. Pain and sedation management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey. *Crit Care*. 2022; 26(1): 87.
8. Dokken M, Aasdahl LV, Huzthyme H, Lydersen S, Skogvoll E. Iatrogenic withdrawal syndrome frequently occurs in paediatric intensive care without algorithm for tapering of analgosedation. *Acta Anaesthesiol Scand*. 2021; 65(7): 928-35.
9. Egbuta C, Mason KP. Current state of analgesia and sedation in the pediatric intensive care unit. *J Clin Med*. 2021; 10(9): 1847.
10. Garcia Guerra G, Joffe AR, Cave D, Hartling L, Curtis S, Jou H, et al. Music use for sedation in critically ill children (MUSiCC trial): study protocol for a pilot randomized controlled trial. *Pilot Feasibility Stud*. 2020; 6: 13.
11. Koizumi T, Kurosawa H. Survey of analgesia and sedation in pediatric intensive care units in Japan. *Pediatr Int*. 2020; 62(5): 535-41.
12. MacDonald I, Tume L, Tasker RC, van den Anker K, Gagiou SA, Trajcev C, et al. A European clinical practice guideline on pain, agitation, delirium, and iatrogenic withdrawal syndrome management in critically ill children: a protocol. *JMIR Res Protoc*. 2024.
13. Neupane B, Snelling PJ, Schlapbach LJ, Gibbons K, Stylianou A, George S, et al. Inflammation and cardiovascular status impact midazolam pharmacokinetics in critically ill children: an observational, prospective, controlled study. *Pharmacol Res Perspect*. 2022; 10(5): e01004.
14. Pedra RAV, Santos AC, Guimarães AVO, Santos BC, Santos BO, da Silva ES. Sedação e analgesia em UTI: protocolos atuais e melhores práticas. *Rev Ibero-Am Humanidades, Ciências e Educação*. 2024; 10(6): 4088-99.
15. Shajan N, Sharma M, Kaur G. Sedation in pediatric intensive care unit and its impact on outcomes of ventilated children: a prospective observational study. *Egypt Pediatr Assoc Gaz*. 2023; 71(1): 50.
16. Taffarel P, Pilar O, Jabornisky R, Pringles P, Valledor S, Alessandrini A, et al. Impact of the implementation of a sedoanalgesia protocol in a pediatric intensive care unit. *Arch Argent Pediatr*. 2023; 121(4): e202202806.
17. Tervonen M, Aikio O, Keikkala E, Hallman M. Dexmedetomidine for pain management and sedation in neonates and infants during

intensive care. Research Square. 2022.

18. Tsvirenko SM, Shkurupiy OA, Shkurupiy VO, Poriadchenko MM, Tsvirenko MS, Martynov AV. Anesthesia or sedation of newborns in intensive care: how to determine the optimal way? *Aktual Probl Suchasnoi Med.* 2022; 22(3-4): 19-23.
19. Yang Y, Traube C, Silver G, Gerber LM. Implementation science in pediatric critical care - sedation and analgesia practices as a case study. *Front Pediatr.* 2022; 10: 864029.
20. Kolmar AR, Kerley L, Melliore MG, Fuller BM. Sedation experiences of pediatric intensive care nurses: Exploring PICU nurse perspectives on sedative management and communication. *J Intensive Care Med.* 2025; 40(1): 60–6.